We sought to analyze the very late outcomes of patients treated for in-stent restenosis (ISR) according to treatment allocation and 10 prespecified variables. BACKGROUND Long-term results (Ͼ2 years) of patients with ISR undergoing repeat coronary interventions are not well established.
Coronary stenting currently represents the default strategy during percutaneous coronary interventions (PCI) (1, 2) . In-stent restenosis (ISR), however, remains the major limitation of this therapy (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Although several mechanical strategies have been proposed in patients with ISR (3-9), several randomized trials have failed to confirm initial expectations (7) (8) (9) . Brachytherapy is highly effective in these patients, but technical and logistic drawbacks limit its use (11) . Drug-eluting stents represent a major therapeutic breakthrough (2, 12, 13) , but larger studies are required before the systematic use of these new devices is justified in all patients with ISR.
Accordingly, there is still a need to gain further insights on the long-term outcome of patients with ISR undergoing repeat PCI. In the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study, 450 patients with ISR were randomized. The acute and mid-term results of this study have been previously reported (8) . The present report describes the long-term (three to five years) clinical outcome of these patients. In addition, we sought to evaluate the influence of 10 "predefined" relevant variables on long-term prognosis.
METHODS
Patients and protocol. The protocol and primary end point of the RIBS trial have been reported (8) . Patients with myocardial ischemia and ISR lesions Ͻ32 mm in length in vessels Ͼ2.5 mm were eligible. Twenty-four sites from Spain and Portugal participated in the trial. All patients received aspirin, and those undergoing repeat stenting also received ticlopidine for one month. Patients were followed-up at 1, 7, and 12 months. Late angiographic follow-up was obtained in 96% of eligible patients (8) . When complete one-year results were available, all participating centers agreed to maintain a close clinical follow-up of these patients. Accordingly, the same detailed standard-ized forms were forwarded to the coordinating center yearly thereafter. Queries about missing or inconsistent data were sent back to the sites. Summaries of clinical records from all patients with potential events were reviewed. Eventually, all events were classified and adjudicated by an independent clinical events committee unaware of the assigned treatment.
Death was considered as cardiac unless a noncardiac cause could be demonstrated. Differentiation between cardiac/ noncardiac death was predefined in the protocol. Myocardial infarction (MI) required two of the following: prolonged (Ͼ30 min) chest pain, new Q waves, and creatine kinase levels Ն2 of the upper normal value (with MB fraction Ͼ10% of total). The composite of death, MI, and target vessel revascularization was a prespecified secondary study end point.
Statistical analysis. Kaplan-Meier curves were constructed to estimate event-free survival. Event-rates were compared with the log-rank test. Cox proportional hazard analyses were used to determine long-term outcome. Hazard ratios were calculated for the 10 relevant prespecified variables (8) . All analyses were performed according to the intention-totreat principle, using the SPSS package (version 12.0, SPSS Inc., Chicago, Illinois). A p value Ͻ0.05 was considered statistically significant.
RESULTS
One year clinical follow-up was obtained in all 450 patients (100% At last clinical follow-up, a total of 37 patients had died (17 ST arm, 20 BA arm), 16 had suffered a MI (6 ST arm, 10 BA arm), 38 had required surgery (20 ST arm, 18 BA arm), and 62 patients had required repeat PCI (27 ST arm, 35 BA arm) (hierarchical ranking). Death was cardiac in 20 cases (6 ST arm, 14 BA arm, p ϭ 0.07), and 10 of these patients died after the first year (1 ST arm, 9 BA arm, p ϭ 0.02). Only two cardiac deaths were sudden (one patient in each group). Angiographically demonstrated abrupt vessel closure associated with an acute coronary syndrome was only seen in one patient in each group (both during the first year of follow-up). Figure 1 displays the event-free survival according to treatment allocation. A nonsignificant trend favoring repeat stenting was found for the combined clinical end point. In addition, a significant reduction in the occurrence of cardiac death/MI (end point not prespecified) was demonstrated after restenting. Cox analysis of the long-term clinical outcome according to the 10 prespecified variables is shown in Figure 2 . Most subgroups showed results consistent with the main outcome measure except for patients with large vessels that presented a significantly better outcome after repeat stenting (hazard ratio 0.51, 95% confidence interval 0.30 to 0.89, p ϭ 0.016). Patients with diffuse ISR (Cox, p ϭ 0.07) and those with lesions in the right or circumflex coronary arteries (Cox, p ϭ 0.02) also had a better prognosis after repeat stenting (Fig. 2) . However, an interaction was found between vessel size and these two variables. The reference vessel diameter was significantly larger in patients with diffuse restenosis (2.94 Ϯ 0.5 mm vs. 2.79 Ϯ 0.5 mm, p Ͻ 0.001) and in non-left anterior descending coronary artery lesions (2.97 Ϯ 0.5 mm vs. 2.74 Ϯ 0.4 mm, p Ͻ 0.001).
Event-free survival for patients with large vessels is depicted in Figure 3 . The better long-term results obtained with repeat stenting were largely driven by a lesser requirement for target vessel revascularization (16% vs. 35%; Cox, p ϭ 0.016). 
DISCUSSION
This study constitutes the longest and most exhaustive clinical follow-up of a large cohort of patients with ISR undergoing repeat PCI. Our follow-up protocol enabled us to obtain a uniquely high rate of late clinical information. In the RIBS study, most adverse events clustered during the first year of follow-up. Although the systematic late angiographic follow-up could have influenced the rate of subsequent target vessel revascularization (14) , by protocol all repeated revascularizations needed to be clinically driven (symptoms or evidence of ischemia). Accordingly, in some patients with recurrent ISR, the procedure was deferred until ischemia could be demonstrated. This could explain the relatively high attrition rate noticed from the sixth month to the end of the first year of follow-up. After this time the rate of new events was markedly reduced, but still a significant number of patients suffer from new events. Previous studies. No previous study has systematically analyzed the late clinical outcome of patients with ISR undergoing repeated mechanical PCI after two years of follow-up. Reimers et al. (3) reported an event-free survival of 81% at 24 months (mean follow-up 27 Ϯ 15 months) in 124 patients with ISR. Bossi et al. (5) followed-up (median 459 days) 234 ISR patients treated with balloon angioplasty and found an event-free survival of 75% at 24 months. Finally, in the meta-analysis of Radke et al. (10) (3,012 ISR patients from 28 studies), the estimated probability of experiencing a major adverse event (mean follow-up 9 Ϯ 4 months) was 30%. The rate of adverse events was comparable among different treatment modalities, and the postprocedural diameter stenosis was the only independent predictor of long-term outcome. Recent data from three large randomized trials confirm these findings demonstrating comparable clinical results at one year, irrespective of the mechanical strategy selected (balloon, rotational atherectomy, cutting balloon, or restenting) (7-9). Conversely, the late outcome of selected patients with ISR undergoing brachytherapy has been examined in detail. The concerns of a potential late "catch-up" phenomenon (delaying rather than preventing restenosis) stimulated longer follow-up studies in small patient subsets. A delayed mitigation of efficacy, associated with a need for late target vessel revascularization, was demonstrated in some irradiated patients (11) . The lifespan of this technology, however, is currently seriously threatened in the era of drug-eluting stents. Present study. Our findings suggest that most patients treated for ISR have a good long-term outcome, but 34% of patients experience at least one adverse event at 4.3 years of follow-up. In addition, our data also indicate the importance of maintaining an adequate clinical follow-up after the first year, considering that some patients (up to 12%) will experience very late adverse events. It should be kept in mind that most patients included in our trial had complex and advanced coronary artery disease (27% diabetics, 43% previous MI, 45% multivessel disease) (8) . These factors and an overall recurrent restenosis rate of 38% (8) could explain the relatively high rates of coronary surgery and mortality at late follow-up.
Interestingly, we found a trend, which did not reach statistical significance, toward a better outcome after repeat stenting in all analyzed clinical outcome measures that emerged in the early period. Although cardiac death and the Alfonso et al. September 6, 2005:756-60 Late Outcome for ISR combined end point of cardiac death/MI at late follow-up were significantly lower after repeat stenting, these findings should be interpreted with caution because they come from post-hoc analyses, and the study design was underpowered to address this issue. Our findings are particularly relevant for patients undergoing repeat stenting because long-term data in this scenario is very limited (8) . Furthermore, this information is also of interest considering that currently most centers are using drug-eluting stents as the workhorse strategy for patients with ISR. Once the benefit of the drug coating is obtained, our results, demonstrating that the presence of two layers of metal on the vessel wall is not associated with any adverse long-term implication, are particularly reassuring.
Another important finding of the current study is that patients with ISR in large vessels do much better after repeat stenting than after balloon angioplasty, and this improved clinical outcome is maintained after 4.3 years. Therefore, the present report confirms our initial findings (8) in this important prespecified patient subset. The better outcome after restenting for patients with diffuse ISR and ISR in locations other than the left anterior descending coronary artery are also noteworthy. However, these two anatomic scenarios were associated with larger vessels, and their clinical implications remain difficult to establish. Finally, some patient subsets (small vessels, focal, left anterior descending coronary artery, and early ISR) do not appear to gain additional clinical benefit from repeat stenting. Study limitations. Only bare-metal stents were used in the RIBS study. The mid-term results of drug-eluting stents in this setting are excellent (12, 13) , but long-term information is eagerly awaited. Because intravascular ultrasound was not systematically performed, its potential implications on longterm outcome were not analyzed. Medical treatment at one year (statins 48%, beta-blockers 63%, and angiotensinconverting enzyme inhibitors 44%) was well balanced in the two groups. However, the potential influence of medical treatment on clinical outcome after this time cannot be established from our study. Conclusions. Patients with ISR undergoing repeat PCI have a significant rate of adverse events at late follow-up. Although most events tend to concentrate during the initial year, a low but steady rate of adverse events occur later on. Accordingly, continued clinical surveillance appears warranted in these patients. Finally, the long-term clinical outcome of patients with ISR in large vessels treated with repeat stenting is favorable.
